Ossur hf
CSE:OSSR
Gross Margin
Ossur hf
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
Country | Company | Market Cap |
Gross Margin |
||
---|---|---|---|---|---|
IS |
O
|
Ossur hf
CSE:OSSR
|
11.3B DKK |
61%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
233.4B USD |
56%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
200.7B USD |
67%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
156.9B USD |
69%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
150.6B USD |
65%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
110.9B USD |
66%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
55.3B EUR |
39%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
45%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
45.9B USD |
79%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
41.8B USD |
61%
|
|
CN |
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
274.4B CNY |
61%
|
Ossur hf
Glance View
Össur hf. is an Icelandic company that stands as a quiet marvel in the realm of orthopedic innovation, specializing in the development of non-invasive equipment designed to enhance human mobility. Born out of a small prosthetics shop in Reykjavik in 1971, the company has grown into a global leader in orthopedic solutions. At its core, Össur's operations revolve around the invention and commercialization of cutting-edge prosthetics, braces, and supports aimed at improving the quality of life for people who face limb challenges due to injuries, disabilities, or age-related conditions. The company's ethos of "Life Without Limitations" guides its pursuit to blend medical technology and engineering in a way that restores human dignity and functionality, manifesting a unique synergy between advanced robotics and biology. Commercially, Össur thrives by leveraging its commitment to research and development, channeling substantial investment into creating high-demand products characterized by reliability, adaptability, and innovation. Revenue streams primarily flow from the sale of prosthetic limbs and associated components, together with orthopedic support products that are distributed both directly and through a network of wholesalers and medical professionals worldwide. By maintaining a diversified product line and focusing on customer-centric customization, Össur meets a significant demand within healthcare systems, insurance providers, and direct consumer markets. The company's ability to translate its scientific prowess into marketable and life-enhancing solutions has cemented its reputation as a key player in the med-tech industry, aligning financial success with a meaningful social mission.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Ossur hf's most recent financial statements, the company has Gross Margin of 61.4%.